This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness evidence was derived from a synthesis of published studies.
Modelling A published decision model, the CORE Diabetes model, was used to assess the long-term clinical and economic consequences of the two treatments in a hypothetical cohort of naive Type 2 diabetes patients. The model was constructed on a series of sub-models, based on Markov cycles, in order to simulate the most important complications of diabetes (cardiovascular disease, eye disease, hypoglycaemia, nephropathy, neuropathy, foot ulcer, amputation, stroke, ketoacidosis, lactic acidosis and mortality). Each sub-model used a Monte Carlo simulation with time, state, time in state and diabetes type-dependent probabilities. This peer-reviewed model had been extensively validated. The time horizon of the model was 35 years.
Outcomes assessed in the review
The clinical outcomes derived from the literature were:
the baseline characteristics of the patient population that entered the model (including demographic and clinical factors), the baseline rates of complications, the proportions of patients taking specific medications or undergoing screening for some complications, and treatment effectiveness.
Study designs and other criteria for inclusion in the review
The primary studies used to derive clinical outcomes were presumably identified selectively, as a systematic review does not appear to have been undertaken. Much of the data on the baseline characteristics of the patients and treatment effects were derived from a published 28-week clinical trial enrolling 233 patients (the INITIATE study) randomised to receive BIAsp 30/70 or insulin glargine. Other data were derived from published studies that were not described.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
The internal validity of the INITIATE study was high because of its randomised design. The validity of the other studies was unclear.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Six primary studies provided the clinical data used in the decision model.
Methods of combining primary studies
The primary estimates were not combined as each study provided a series of clinical estimates.
Investigation of differences between primary studies
Results of the review
The baseline characteristics of the study population were as follows: mean duration of diabetes, 9 years; mean HbA1c, 9.77%.
The following baseline patient characteristics were considered.
The rate of hypertensive heart disease was 0%.
The rate of angina pectoris was 1.72%.
The rate of myocardial infarction was 2.15%.
The rate of heart failure was 0.43%.
The rate of cardiac dysrhythmia was 1.29%.
The rate of stroke was 0%.
The rate of peripheral vascular disease was 0.86%.
The rate of peripheral neuropathy was 23.2%.
The rates of foot ulcer and amputation were 0.43%.
The rates of microalbuminuria and gross proteinuria were 4%.
The rate of background diabetes retinopathy was 8.5%.
The rate of proliferative diabetic retinopathy was 0%.
The rate of blindness and low vision was 8.5%.
The rate of cataract was 4.3%.
The rate of macular oedema was 0%.
The proportion of patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was 20.6%.
The proportion of patients taking statins was 17.8%.
The proportion of patients taking aspirin was 7.7%.
The rates of patients screened for retinopathy, renal disease and foot disease were 63.2%, 60% and 37.3%, respectively.
In terms of the effectiveness of treatment, the change from baseline in HbA1c was -2.79% with BIAsp 30/70 and -2.36% with glargine.
The change from baseline in BMI was +1.88 kg/m2 with BIAsp 30/70 and +1.22 kg/m2 with glargine.
The increase from baseline in total dose of insulin (in units per kg of body weight) was +0.82 with BIAsp 30/70 and +0.55 with glargine.
Transition probabilities were based on the published CORE Diabetes Model and were not reported.
Measure of benefits used in the economic analysis
The summary benefit measures used were the life-years (LYs) and quality-adjusted life-years (QALYs). These were
